HURA (TuHURA Biosciences) Pre-Tax Income : $-12.27 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. TuHURA Biosciences's pretax income for the three months ended in Dec. 2024 was $0.00 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-12.27 Mil. TuHURA Biosciences's pretax margin was %.

TuHURA Biosciences Pre-Tax Income Historical Data

The historical data trend for TuHURA Biosciences's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Pre-Tax Income Chart

TuHURA Biosciences Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

-7.02

-9.37

-29.32

-21.68

TuHURA Biosciences Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial				-	-4.84	-5.27	-2.16	-

Competitive Comparison of TuHURA Biosciences's Pre-Tax Income

For the Biotechnology subindustry, TuHURA Biosciences's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TuHURA Biosciences's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TuHURA Biosciences's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where TuHURA Biosciences's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

TuHURA Biosciences Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

TuHURA Biosciences's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-17.592	+	-0.314	+	-4.138	+	0.362	+	0
	=	-21.68

TuHURA Biosciences's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	0	+	0	+	0	+	0	+	0
	=	0.00

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.27 Mil.

TuHURA Biosciences (NAS:HURA) Pre-Tax Income Explanation

TuHURA Biosciences's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	0	/	0
	=	%

TuHURA Biosciences Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

TuHURA Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612

Website

https://www.tuhurabio.com

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.